Keywords: Merck & Co, Gardasil, Zolinza, Cubicin, Japan, Cervical cancer, Lymphomas, MRSA
Merck & Co strengthens its portfolio in key market, getting Japanese approval for Gardasil, Zolinza and Cubicin
Article | 04 July 2011
US drug giant Merck & Co (NYSE: MRK) revealed on Friday that the Japanese Ministry of Health, Labor and Welfare ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
